Blood test may offer alternative to that dreaded colonoscopy

Pedersen, Amanda
August 2007
Medical Device Daily;8/10/2007, Vol. 11 Issue 152, p1
The article focuses on the serum-based diagnostic test for colorectal cancer detection, developed by diagnostic tests manufacturer BioServe and biochemical research company Phenomenome Discoveries. The companies developed the blood test to provide an alternative to coloscopy on colorectal cancer diagnosis. It is available in Canada and Japan and will be launched in the U.S. in the fourth quarter of 2007.


Related Articles

  • Blood test may offer alternative to that dreaded colonoscopy. Pedersen, Amanda // Diagnostics & Imaging Week;8/16/2007, Vol. 10 Issue 33, p1 

    The article provides information on the serum-based diagnostic test developed by Laurel, Maryland-based BioServe and Canadian company Phenomenome Discoveries for the identification of colorectal cancer and pre-cancerous states conducive to the development of colorectal cancer. The test is unlike...

  • Early diagnosis of colorectal cancer: a review. Hardcastle, J. D.; Armitage, N. C. // Journal of the Royal Society of Medicine;Aug1984, Vol. 77 Issue 8, p673 

    The article focuses on the study of early diagnosis of colorectal cancer. The detection of occult blood in faeces is at present the only practical method of population screening for colorectal cancer and can be performed using a guaiac-impregnated slide test such as Haemoccult. Its use in...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/7/2007, Vol. 18 Issue 152, p2 

    This section offers news briefs on the biotechnology industry. Abraxis BioScience Inc. has entered into an agreement with the Buck Institute for Age Research. Avanir Pharmaceuticals has completed the sale of antipsychotic drug FazaClo to Azur Pharma. BioServe and Phenomenome Discoveries Inc....

  • Early detection: The ease of detection. Greenwood, Emma // Nature Reviews Cancer;Apr2003, Vol. 3 Issue 4, p235 

    Cites a study conducted by researchers Andrew Feinberg et al., published in 14 March 2003 issue of the journal 'Science,' on the efficacy of a technique called loss of imprinting (LOI) to predict the risk of developing colorectal cancer. Potential of genetic and epigenetic changes to initiate...

  • Screening for colorectal cancer1 1Liebermann DA, Weiss DG One-Time Screening for Colorectal Cancer With Combined Fecal Occult-Blood Testing (FOBT) and Examination of the Distal Colon NEJM 2001;345:555–60 Alazmi, Waleed M.; Barkin, Jamie S. // American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1837 

    This report is on the yield of one-time screening for colorectal cancer with combined fecal occult blood tests (FOBTs) and examination of the distal colon. The study population included 2885 subjects without symptoms who underwent one-time FOBT and colonoscopy. The information obtained from the...

  • Costs of bowel Ca screening to soar.  // Pulse;3/15/2007, Vol. 67 Issue 10, p15 

    The article focuses on a new British analysis which warns that bowel cancer screening will send demand for endoscopy by 69%. Figures based on the British colorectal cancer screening pilot suggest the resulting costs are expected to outstrip the allocated cash. About 1.9% of patients are likely...

  • COLORECTAL CANCER. Round, Alison; Weller, David // Pulse;3/22/2007, Vol. 67 Issue 11, p46 

    The article discusses the benefits of medical screening for early identification of colorectal cancer. The incidence of bowel cancer is highest in Great Britain but survival rates have improved due to early diagnosis and screening. Fecal occult blood testing is considered at the only method of...

  • Proliferation happens. Ahnen, Dennis J.; Byers, Tim; Ahnen, D J; Byers, T // JAMA: Journal of the American Medical Association;9/23/98, Vol. 280 Issue 12, p1095 

    Editorial. Discusses the appeal of using surrogate end points in trials of colonic cancer chemoprevention. Testing of potential agents; Research by Holt et al in this issue; Benefits of increased consumption of low-fat dairy foods; Two questions about surrogate end points in reference to...

  • JOHNS HOPKINS DEVELOPS COLON CANCER BLOOD TEST.  // Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p7 

    Focuses on a blood test developed by researchers at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute with Indivumed for the diagnosis of colon cancer. Cancer genes detected in the blood of colorectal cancer patients; Background of Indivumed.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics